European Journal of Surgical Oncology
Volume 33, Issue 1 , Pages 7-15 , February 2007

Angiopoietins in malignancy

,Accepted 28 July 2006.

References 

  1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:257–259
  2. Yancopoulos GD, Klagsbrun , Folkman J. Vasculogenesis, angiogenesis and growth factors: ephrins enter the fray at the border. Cell. 1998;93:661–664
  3. Fukumura D, Xavier R, Sugiura T, et al. Tumour induction of VEGF promoter activity in stromal cells. Cell. 1998;94:715–725
  4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364
  5. Davis S, Aldrch TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the Tie2 Receptor, by secretion-trap expression cloning. Cell. 1996;87:1161–1169
  6. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60
  7. Davis S, Yancopoulos GD. The angiopoietins: Yin and Yang in angiogenesis. Curr Top Microbiol Immunol. 1999;237:173–185
  8. Loughna S, Sato TN. Angiopoietin and Tie signalling pathways in vascular Development. Matrix Biol. 2001;20(5–6):319–325
  9. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodelling. Exp Cell Res. 2006;312:630–641
  10. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, Regression and Growth in tumours mediated by angiopoietins and VEGF. Science. 1999;284:1994–1998
  11. Hawighorst T, Skobe M, Streit M, et al. Activation of the Tie 2 receptor by angiopoietin 1 enhances tumour vessel maturation and impairs squamous cell carcinoma. Am J Pathol. 2002;160:1381–1392
  12. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumour angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001;61:2145–2153
  13. Ahmad SA, Liu W, Jung YD, et al. Differential expression of angiopoietin-1 and angiopoietin-2 in colorectal carcinoma. Cancer. 2001;92:1138–1143
  14. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumour angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999;18:5356–5362
  15. Valenzuela DM, Griffiths JA, Rojas J, et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. PNAS. 1999;96:1904–1909
  16. Lee HJ, Cho CH, Hwang SJ, et al. Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J. 2004;18:1200–1208
  17. Nakayama T, Yoshizaki A, Kawahara N, et al. Expression of Tie-1 and 2 receptors, and angiopoietin-1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors. Histopathology. 2004;44:232–239
  18. Nakayama T, Hatachi G, Wen CY, et al. Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol. 2005;11:964–969
  19. Iwama A, Hamaguchi I, Hashiyama M, Murayama Y, Yasunaga K, Suda T. Molecular cloning and characterisation of mouse tie and tek receptor tyrosine kinase genes and their expression in haematopoietic stem cells. Biochembiophys Res Comm. 1993;195:301–309
  20. Schnürch H, Risau W. Expression of Tie2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development. 1993;119:957–968
  21. Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol. 2002;198:502–510
  22. Lauren J, Gunjiu Y, Alitalo K. Is angiopoietin-2 necessary for the initiation of tumour angiogenesis?. Am J Pathol. 1998;153:1333–1339
  23. Batard T, Sansilvestri P, Scheinecker C, et al. The Tie receptor tyrosine kinase is expressed by human haematopoietic progenitor cells and a subset of megakaryocytic cells. Am Soc Haematol. 1996;87:2212–2220
  24. William C, Koehne P, Jurgensen JS, et al. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circulation Res. 2000;87:370–377
  25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  26. Kalinski T, Krueger S, Sel S, Werner K, Ropke M, Roessner A. Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interleukin-1beta. Cancer. 2006;106(9):2028–2038
  27. Tanaka S, Sugimachi K, Yamashita Y, et al. Angiogenic switch as a molecular target of malignant tumours. J Gastroenterol. 2003;38:93–97
  28. Ahmad SA, Liu W, Jung YD, et al. The effects of angiopoietin-1 and -2 on tumour growth and angiogenesis in human colon cancer. Cancer Res. 2001;61:1255–1259
  29. Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T, Sugimachi K. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumour progression. Surgery. 2002;131:S135–S141
  30. Hayes AJ, Huang WQ, Yu J, et al. Expression and function of angiopoietin-1 in breast cancer. Br J Cancer. 2000;83:1154–1160
  31. Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumours. Cancer Res. 2003;63:3370–3377
  32. Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis. Br J Cancer. 2002;87:1182–1187
  33. Tian S, Hayes AJ, Metheny-Barlow LJ, Li LY. Stabilisation of breast cancer xenograft tumour neovasculature by angiopoietin-1. Br J Cancer. 2002;86:645–651
  34. Hu B, Guo P, Fang Q, et al. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotein-2. Proc Natl Acad Sci USA. 2003;100:8904–8909
  35. Yoshiji H, Kuriyama S, Noguchi R, et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut. 2005;54(12):1768–1775
  36. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004;6(5):507–516
  37. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, Plate KH. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol. 2004;165(5):1557–1570
  38. Shim WS, The M, Bapna A, et al. Angiopoietin 1 promotes tumour angiogenesis and tumour vessel plasticity of human cervical cancer in mice. Exp Cell Res. 2002;279:299–309
  39. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest. 1999;103:341–345
  40. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology. 2003;37:1105–1113
  41. Zhao ZC, Zheng SS, Wan YL, et al. The effect of pro-angiogenesis factors and their receptors on angiogenesis in hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi [Chin J Oncol]. 2004;26(8):472–475
  42. Wang J, Wu K, Zhang D, et al. Expressions and clinical significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem Biophys Res Commun. 2005;337(1):386–393
  43. Sfiligoi C, De Luca A, Cascone I, et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer. 2003;103:466–474
  44. Brown LF, Dezube BJ, Tognazzi , Dvorak HF, Yancopoulos GD. Expression of tie1, tie2 and angiopoietins 1, 2 and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol. 2000;156:2179–2183
  45. Durkin AJ, Bloomston M, Yeatman TJ, et al. Differential expression of the Tie2 receptor and its ligands in human pancreatic tumors. J Am Coll Surg. 2004;199(5):724–731
  46. Takanami I. Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis. Oncol Rep. 2004;12(4):849–853
  47. Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H, Miyazaki K. Expression of angiopoietin-1, angiopoietin-2 and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology. 2002;62:340–348
  48. Wong MP, Chan SY, Fu KH, et al. The angiopoietins, Tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinoma. Lung Cancer. 2000;29:11–22
  49. Tanaka F, Ishikawa S, Yanagahara R, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 2002;62:7124–7129
  50. Lind AJ, Wikstrom P, Granfors T, Egevad L, Stattin P, Bergh A. Angiopoietin 2 expression is related to histological grade, vascular density, metastases and outcome in prostate cancer. Prostate. 2005;62(4):394–399
  51. Li C, Feng HC, Chen JC, Song YF. Expression and significance of angiopoietin-1 and angiopoietin-2 in oral squamous cell carcinoma. AI Zheng. 2005;24(11):1388–1393
  52. Wu YX, Liang P, Nan XR, Jiao YJ, Sun XJ. Expression and significance of angiopoietins in oral squamous cell carcinoma. Hua Xi Kou Qiang Yi Xue Za Zhi. 2005;23(1):63–6468
  53. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol. 1998;153:1459–1466
  54. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumour angiogenesis. Exp Neurol. 1999;159:391–400
  55. Nakayama T, Hatachi G, Wen CY, et al. Expression and significance of Tie1 and Tie2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol. 2005;11(7):964–969
  56. Takahama M, Tsutsumi M, Tsujiuchi T, et al. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell carcinomas. Clin Cancer Res. 1999;5:2506–2510
  57. Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO, Kagawa S. Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int. 2005;95(4):660–663
  58. Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol. 1997;157:2329–2333
  59. Ferrer FA, Milller LJ, Lindquist R, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 1999;54:567–572
  60. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res. 2000;6:1882–1890
  61. Kollerman J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor flk-1 in benign, premalignant and malignant prostate tissue. Am J Clin Pathol. 2001;116:115–121
  62. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol. 2004;204:1–10
  63. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–248

PII: S0748-7983(06)00282-4

doi: 10.1016/j.ejso.2006.07.015

European Journal of Surgical Oncology
Volume 33, Issue 1 , Pages 7-15 , February 2007

Article Tools

* Image Usage & Resolution